Literature DB >> 12839957

Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.

James R Bading1, Paul B Yoo, John D Fissekis, Mian M Alauddin, David Z D'Argenio, Peter S Conti.   

Abstract

Drug uptake and anabolism by tumors are prerequisites of response to 5-fluorouracil (5-FU). Positron emission tomography (PET) with 5-[(18)F]FU (PET/5-[(18)F]FU) is potentially useful for noninvasive measurement of these processes, but is severely hampered by rapid catabolism of 5-[(18)F]FU in vivo. This study explored the combined use of PET/5-[(18)F]FU and eniluracil (5-ethynyluracil), a potent inhibitor of 5-FU catabolism, to measure the pharmacokinetics of 5-FU uptake and metabolism in tumors. Rats bearing a s.c. implanted rat colon tumor were given eniluracil and injected i.v. with 5-[(18)F]FU. Dynamic PET and arterial blood sampling were performed 0-2 h. Tumors (n = 5) were then rapidly excised, frozen, and analyzed for labeled metabolites by high performance liquid chromatography. Tumor TACs were analyzed by compartmental modeling. Compartments were identified with molecular species by comparison with ex vivo assays. Tumor extracellular fluid volume was determined in a separate group of rats. Kinetic analysis indicated partial trapping of (18)F within tumors 0-2 h after injection. Tumor time-activity curves conformed closely to a catenary 3-compartment, 5-parameter model. The model yielded values for 5-FU clearance from plasma into the trap that agreed closely with those reported previously for gastrointestinal tumors from a PET/5-[(18)F]FU + eniluracil study in humans. Tumor extracellular fluid volume as measured with (99m)Tc DTPA [(3.1 +/- 0.2) x 10(-1) ml/g; n = 5] agreed well with the distribution volume for compartment 1 of the 3-compartment, 5-parameter model [(3.7 +/- 0.3) x 10(-1) ml/g; n = 5], thus indicating that compartment 1 corresponds to tumor extracellular space. Compartment 3 closely matched the combined magnitudes of (18)F fluoronucleoside (FN) triphosphates and macromolecules in all of the cases, and compartment 2 was quantitatively consistent with the sum of intracellular 5-FU, FNs, and FN mono- and diphosphates. These observations show that PET/5-[(18)F]FU combined with an inhibitor of 5-FU catabolism and compartmental modeling is capable of quantifying the following for 5-FU in tumors: distribution volume in the extracellular space, cell transport, size and turnover rate of an intermediate intracellular pool, and formation of a long-lived intracellular pool comprising FN triphosphates + macromolecules. Such information could be useful in predicting tumor response to 5-FU, formulating protocols that increase delivery of 5-FU into tumor cells, and modulating 5-FU kinetics to overcome tumor resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839957

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

2.  Scheduling of anticancer drugs: timing may be everything.

Authors:  Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

3.  The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

Authors:  Yasuhiro Tsume; Chester J Provoda; Gordon L Amidon
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-03-05       Impact factor: 3.205

Review 4.  Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.

Authors:  Wolfgang A Weber; Johannes Czernin; Michael E Phelps; Harvey R Herschman
Journal:  Nat Clin Pract Oncol       Date:  2008-01

Review 5.  Positron emission tomography imaging of small animals in anticancer drug development.

Authors:  Eric O Aboagye
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

6.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.